SCHEMBL6281787

SCHEMBL6281787

CC(=O)Nc1c(C)ccc(Cl)c1CO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
LMNA P02545 1/20 0.44
PKM P14618 2/20 0.42
GAA P10253 1/20 0.42
CDC7 O00311 1/20 0.40
PLK4 O00444 1/20 0.40
DYRK3 O43781 1/20 0.40
JAK2 O60674 1/20 0.40
ROCK2 O75116 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
INSR P06213 1/20 0.40
CDK1 P06493 1/20 0.40
ROS1 P08922 1/20 0.40
PIM1 P11309 1/20 0.40
FGFR1 P11362 1/20 0.40
PRKACA P17612 1/20 0.40
FLT1 P17948 1/20 0.40
RPS6KB1 P23443 1/20 0.40
CDK2 P24941 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11057175 0.87 ALDH1A1 (0.44) ALDH1A1LMNAPKMGAACDC7
SCHEMBL6243369 0.79 ALDH1A1 (0.56) ALDH1A1LMNAPKMGAACDC7
SCHEMBL8130619 0.75 ALDH1A1 (0.67) ALDH1A1LMNAGAACDC7PLK4
SCHEMBL17553923 0.74 CDC7 (0.43) ALDH1A1LMNAPKMCDC7PLK4
SCHEMBL9899179 0.72 ALDH1A1 (0.46) ALDH1A1LMNAPKMGAACDC7
SCHEMBL15000245 0.72 ALDH1A1 (0.42) ALDH1A1PKMSMN1; SMN2MAPTHPGD
SCHEMBL2921682 0.72 PDK1 (0.58) ALDH1A1GAASMN1; SMN2HPGDS1PR2
SCHEMBL10988570 0.71 CDC7 (0.41) ALDH1A1LMNAPKMCDC7PLK4
SCHEMBL11522426 0.71 RORC (0.49) ALDH1A1PKMGAASMN1; SMN2MAPT
SCHEMBL15765841 0.71 MAPT (0.49) ALDH1A1LMNAPKMGAACDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849632-B2 Heteroaryl alkyl piperazine derivatives CV THERAPEUTICS, INC. (US) 2005-02-01 US disclosed
US-20040192702-A1 Heteroaryl alkyl piperazine derivatives ZABLOCKI JEFF (US) 2004-09-30 US disclosed
US-20030216409-A1 Heteroaryl alkyl piperazine derivatives CV THERAPEUTICS, INC. 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192702-A1 Heteroaryl alkyl piperazine derivatives ATP2A1, CPT1B, ATP2A3 ALDH1A1 110/4885LMNA 3166/4885PKM 368/4885
US-20030216409-A1 Heteroaryl alkyl piperazine derivatives ATP2A1, CPT1B, ATP2A3 ALDH1A1 110/4885LMNA 3166/4885PKM 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.